These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3471281)

  • 1. Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
    Talpaz M; Kantarjian HM; McCredie KB; Keating MJ; Trujillo J; Gutterman J
    Blood; 1987 May; 69(5):1280-8. PubMed ID: 3471281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
    Talpaz M; Kantarjian HM; McCredie K; Trujillo JM; Keating MJ; Gutterman JU
    N Engl J Med; 1986 Apr; 314(17):1065-9. PubMed ID: 3457264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
    Blood; 1988 Aug; 72(2):642-7. PubMed ID: 3165298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
    Kantarjian HM; Keating MJ; Talpaz M; Walters RS; Smith TL; Cork A; McCredie KB; Freireich EJ
    Am J Med; 1987 Sep; 83(3):445-54. PubMed ID: 3477958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia.
    Kantarjian HM; Keating MJ; Walters RS; McCredie KB; Smith TL; Talpaz M; Beran M; Cork A; Trujillo JM; Freireich EJ
    Cancer; 1986 Nov; 58(9):2023-30. PubMed ID: 3463397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia.
    Schofield JR; Robinson WA; Murphy JR; Rovira DK
    Ann Intern Med; 1994 Nov; 121(10):736-44. PubMed ID: 7944050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
    Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients.
    Talpaz M; Spitzer G; Hittelman W; Kantarjian H; Gutterman J
    Exp Hematol; 1986 Aug; 14(7):668-71. PubMed ID: 3460811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myelogenous leukaemia: haematological remissions with alpha interferon.
    Talpaz M; McCredie K; Kantarjian H; Trujillo J; Keating M; Gutterman J
    Br J Haematol; 1986 Sep; 64(1):87-95. PubMed ID: 3463363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase.
    Wahlin A; Holm J; Engman K
    Acta Oncol; 1991; 30(5):611-5. PubMed ID: 1892679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia. Results of a multicenter study.
    Werter M; de Witte R; Janssen J; de Pauw B; Haanen C
    Blut; 1988 May; 56(5):209-12. PubMed ID: 3285912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation.
    Higano CS; Raskind WH; Singer JW
    Blood; 1992 Sep; 80(6):1437-42. PubMed ID: 1520870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia.
    Yoffe G; Blick M; Kantarjian H; Spitzer G; Gutterman J; Talpaz M
    Blood; 1987 Mar; 69(3):961-3. PubMed ID: 2880616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
    O'Brien S; Witt R; Talpaz M; Kantarjian H
    Cancer; 1991 Apr; 67(7):1946-9. PubMed ID: 2004308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
    Kantarjian HM; Smith TL; O'Brien S; Beran M; Pierce S; Talpaz M
    Ann Intern Med; 1995 Feb; 122(4):254-61. PubMed ID: 7825760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alfa-2b in the treatment of chronic myelogenous leukemia.
    Niederle N; Kloke O; Osieka R; Wandl U; Opalka B; Schmidt CG
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):29-35. PubMed ID: 3473689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.
    Kantarjian HM; Vellekoop L; McCredie KB; Keating MJ; Hester J; Smith T; Barlogie B; Trujillo J; Freireich EJ
    J Clin Oncol; 1985 Feb; 3(2):192-200. PubMed ID: 3855444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.